$福泰制药(VRTX)$ asn解读会议：

And just hold that in your mind and just think about KALYDECO is to CF, as what I think VX-407 is going to be to ADPKD, the first of serial innovation, and we will get to everyone over time

And a real look into the future, this is the ADPKD program. And the highlight here is just like in CF, where the underlying cause of disease is a misfolded protein,..., but it remains true that the only medicines that we know of, small molecules, that properly refold a misfolded protein to lead to therapeutic benefit are the CFTR modulators

饼先吃下了